Back to the main directory
EarningsReview / Equity
- Transition year by BNP Paribas Exane
- Rusta (Buy, TP: SEK88.00) - Neutral Q3, solid start to Q4 by DnB Markets
- Zealand Pharma (Buy, TP: DKK1150.00) - Deal delivery by DnB Markets
- SSAB (Buy, TP: SEK82.00) - Sweet spot exposure by DnB Markets
- Navigator Holdings Ltd Minor model adjustments by DnB Markets
- Itaú BBA on LWSA: In-Line Operating Trends; Bottom Line Miss by Itau
- Itaú BBA on Adecoagro: 4Q24 – Neutral Q; Better S&E Prospects for FY25 Volumes, but Still Pending For Better Sugar Prices by Itau
- PA Good Doctor (1833 HK) by HSBC
- TIME Conference Guide by BNP Paribas Exane
- Improving momentum: Upgrade to Outperform by BNP Paribas Exane
- Downgrade to Neutral as headwinds build by BNP Paribas Exane
- End of the downgrade cycle: Upgrade to Outperform by BNP Paribas Exane
- GenAI in action by BNP Paribas Exane
- Supportive print by BNP Paribas Exane
- Overlooked value by BNP Paribas Exane
- Defensive greenshoots, but progress comes with a price by BNP Paribas Exane
- Mixed FY24 results and potentially cautious guidance for Q1 25 by BNP Paribas Exane
- Prices, volumes, arbitrage opportunities, and implications on company profits by BNP Paribas Exane
- Q4'24 results: Strong finish to the year; EUR1bn savings by 2030 by BNP Paribas Exane
- Q4 First Take: Better than it looks, but not much by BNP Paribas Exane
- Merz Bundestag comments & RWE disposal headlines by BNP Paribas Exane
- STEF - Pire que prévu by MidCap Partners
- Eurobio Scientific - Deux nouvelles opérations by MidCap Partners
- Luvelta’s discontinuation - a slight positive for GMAB’s Rina-S by BNP Paribas Exane
- Virbac - A transition in 2025 after a very successful 2024 by MidCap Partners